Neuren Pharmaceuticals Limited (AU:NEU) has released an update. Neuren Pharmaceuticals Limited has announced promising Phase 2 clinical trial results for NNZ-2591, showing significant improvements in ...
Australian biopharmaceutical company Neuren Pharmaceuticals has announced positive top-line data from its Phase II trial of NNZ-2591, a treatment for children with Pitt Hopkins syndrome (PTHS). PTHS ...
(RTTNews) - Neuren Pharmaceuticals (NEU.AX) announced positive results from its Phase 2 clinical trial of NNZ-2591 in children with Pitt Hopkins syndrome (PTHS). Statistically significant improvement ...
TipRanks on MSN
Neuren wins Health Canada nod to expand phase 3 trial of NNZ-2591 in Phelan-McDermid syndrome
Neuren Pharmaceuticals Limited ( ($AU:NEU) ) has provided an announcement. Neuren Pharmaceuticals has secured Health Canada approval for its ...
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) today announced that it has expanded its current licensing agreement for trofinetide with Neuren Pharmaceuticals to acquire ...
Neuren Pharmaceuticals, a company develops new drug therapies to treat multiple serious neurological disorders, announced top-line results from its phase 2 clinical trial of NNZ-2591 in children with ...
PERTH, Australia – Melbourne-based Neuren Pharmaceuticals Ltd. will be able to progress NNZ-2591 to the clinic for three orphan indications after raising AU$20 million (US$13.75 million) in a ...
MELBOURNE, Australia--(BUSINESS WIRE)--Neuren Pharmaceuticals (ASX: NEU) today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to Neuren’s NNZ-2591 for the ...
Acadia Pharmaceuticals Inc (NASDAQ:ACAD) shares are trading higher after the company expanded its current licensing agreement for trofinetide with Neuren Pharmaceuticals to acquire ex-North American ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback